W Taal

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. doi request reprint Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics
    Walter Taal
    Department of Neuro Oncology Neurology, Erasmus MC Cancer Institute, Erasmus MC University Medical Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    J Neurooncol 121:365-72. 2015
  2. pmc Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study
    Walter Taal
    Department Neurology Neuro oncology Unit, Erasmus MC University Hospital Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    J Neurooncol 108:195-200. 2012
  3. ncbi request reprint [Favourable result for temozolomide in recurrent high-grade glioma]
    W Taal
    Erasmus MC, locatie Daniel den Hoed Oncologisch Centrum, Postbus 5201, Rotterdam
    Ned Tijdschr Geneeskd 149:1393-9. 2005
  4. doi request reprint Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
    Walter Taal
    Department of Neuro Oncology Neurology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 113:405-10. 2008
  5. pmc First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response
    Walter Taal
    Department of Neuro Oncology Neurology, Erasmus MC, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Neuro Oncol 13:235-41. 2011
  6. doi request reprint IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
    H J Dubbink
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Neurology 73:1792-5. 2009
  7. ncbi request reprint Two exceptional phenomena in an anaplastic oligo-astrocytoma
    M C J Hanse
    Neuro Oncology Unit, Daniel den Hoed Oncology Center, Erasmus University Medical Center, Rotterdam, The Netherlands
    J Neurooncol 78:197. 2006
  8. doi request reprint Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
    Dieta Brandsma
    Department of Neuro Oncology, Daniel den Hoed Cancer Centre, Erasmus Medical Centre, Rotterdam, Netherlands
    Lancet Oncol 9:453-61. 2008

Detail Information

Publications8

  1. doi request reprint Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics
    Walter Taal
    Department of Neuro Oncology Neurology, Erasmus MC Cancer Institute, Erasmus MC University Medical Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    J Neurooncol 121:365-72. 2015
    ....
  2. pmc Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study
    Walter Taal
    Department Neurology Neuro oncology Unit, Erasmus MC University Hospital Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    J Neurooncol 108:195-200. 2012
    ..Our data do not suggest superior efficacy of this schedule as compared to the standard day 1-5 every 4 weeks schedule...
  3. ncbi request reprint [Favourable result for temozolomide in recurrent high-grade glioma]
    W Taal
    Erasmus MC, locatie Daniel den Hoed Oncologisch Centrum, Postbus 5201, Rotterdam
    Ned Tijdschr Geneeskd 149:1393-9. 2005
    ..To describe the results of the treatment of recurrent glioma with temozolomide...
  4. doi request reprint Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
    Walter Taal
    Department of Neuro Oncology Neurology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 113:405-10. 2008
    ..The occurrence of early pseudo-progression was retrospectively assessed in a cohort of malignant glioma patients treated with RT/TMZ...
  5. pmc First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response
    Walter Taal
    Department of Neuro Oncology Neurology, Erasmus MC, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Neuro Oncol 13:235-41. 2011
    ..01) and a methylated MGMT promoter (P = .02). We conclude that MGMT promoter methylation and IDH1 mutations seem to predict survival from the time of diagnosis, but not PFS to TMZ...
  6. doi request reprint IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
    H J Dubbink
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Neurology 73:1792-5. 2009
    ....
  7. ncbi request reprint Two exceptional phenomena in an anaplastic oligo-astrocytoma
    M C J Hanse
    Neuro Oncology Unit, Daniel den Hoed Oncology Center, Erasmus University Medical Center, Rotterdam, The Netherlands
    J Neurooncol 78:197. 2006
  8. doi request reprint Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
    Dieta Brandsma
    Department of Neuro Oncology, Daniel den Hoed Cancer Centre, Erasmus Medical Centre, Rotterdam, Netherlands
    Lancet Oncol 9:453-61. 2008
    ..Further research is needed to establish reliable imaging parameters that distinguish between true tumour progression and pseudoprogression or treatment-related necrosis...